Skip to main content
Search
Search
About Angelman Syndrome
About FAST
For Researchers
Welcome
Apply for a Grant
Grant Application Process
FAST-Funded Research
For Pharma
Welcome
The Pharma-Research-Community Hub
FAST Ventures
Resources
For Families & Caregivers
Welcome
Newly Diagnosed?
Understanding AS Genetics and Genotypes
Treatment & Trials
Get Involved
Resources for Caregivers
For Donors & Investors
Welcome
Ways to Give
Cure Angelman Now (CAN)
FAST Ventures
Contact Us
Donate
Donate
Menu
Angelman Syndrome News
Sort by category
Families & Caregivers
Research
Pharma
Donors & Investors
Latest
All
05/16/2024
Ionis announces positive topline results from Phase 1/2a trial of ION582 for Angelman syndrome
05/14/2024
Purdue WellCast Study
05/14/2024
Skating Angels host their Annual Hockey Tournament
05/14/2024
Understanding Clinical Outcome Assessments (COAs) Used in Clinical Trials
04/30/2024
Newly published article on research exploring the epigenetic landscape of Angelman syndrome
04/30/2024
2023 CAN Grand Prize Trip
04/22/2024
FAST’s Genetic Services & Education
04/17/2024
April 17, 2024 Newsletter | What to Know
04/15/2024
Ultragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102
04/01/2024
Dr. Cesar Ochoa-Lubinoff
04/01/2024
Welcoming FAST Germany
04/01/2024
FAST LatAm Updates
03/19/2024
Inaugural Angelman Syndrome Congressional Advocacy Day Round-Up
03/19/2024
Global Spotlight: Heather Brady
03/07/2024
Family Advocates Urge Congress’ Support During Inaugural Angelman Syndrome Congressional Advocacy Day
03/05/2024
MENA Angelman Symposium Q&A
03/05/2024
New FAST-TRAC grant collaboration with Dr. Alvin Huang
03/05/2024
How Clinical Trials Work
02/29/2024
A Message from Lauren Black
02/21/2024
International Angelman Day 2024 Round-Up
02/20/2024
Rare Disease Week 2024
02/07/2024
Warrior Wednesday: Kristina
01/03/2024
Ultragenyx Pharmaceutical Ultragenyx announces completion of enrollment in Global Phase 1/2 Trial of GTX-102
12/19/2023
2023 Year in Review